Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ATYR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsaTyr Pharma files routine investor presentation materials for June 2026 conferences
Filed June 1, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
low
Company furnished updated corporate presentation materials dated June 2026 under Regulation FD, to be used at investor meetings, conferences, and analyst discussions.
Item 7.01 verify on EDGAR → -
low
Presentation materials will be posted on company website to ensure fair dissemination of information to all investors.
Exhibit 99.1 view on EDGAR →
Summary
aTyr Pharma filed a routine 8-K to disclose updated investor presentation materials dated June 2026. The company will use these materials at upcoming investor conferences, meetings with stockholders and analysts, and will post them on its corporate website. This is a standard Regulation FD filing to ensure all investors have equal access to company information presented at such events.
For retail investors, this filing has minimal immediate impact. It signals the company is actively engaging with the investment community, which is normal business practice. The actual content of the presentation may contain updated business metrics, pipeline progress, or strategic updates. Investors should review the presentation materials on the company's investor relations website to see if any new information about clinical trials, partnerships, or financial guidance has been disclosed.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1
Corporate Presentation Materials of aTyr Pharma, Inc. dated June 2026
The company filed corporate presentation materials dated June 2026 as Exhibit 99.1. This is a routine disclosure of investor presentation materials, typically used for conferences, investor meetings, or roadshows. The actual content and materiality depend on what is disclosed in the presentation itself, which is not included in this 8-K body.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
aTyr Pharma, Inc. (the Company) intends to use an investor presentation to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website. A copy of the presentation materials is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The company is furnishing new investor presentation materials under Regulation FD that will be used for investor meetings, analyst discussions, and conferences. The materials are attached as Exhibit 99.1 and will be posted on the company's website. This is a routine disclosure to ensure fair dissemination of information to all investors.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify